title: Effect of sertraline on regional metabolic rate in patients with affective disorder.
abstract: Seventeen patients with major affective disorder completed a 10-week, placebo-controlled, randomized trial of the serotonin reuptake inhibitor sertraline. Patients underwent positron emission tomography with 18F-deoxyglucose and were assessed with the Hamilton Depression Rating Scale at baseline and 10 weeks after treatment with sertraline or placebo. The middle frontal gyrus, an area previously characterized by decreased metabolic activity in depressive patients, showed relatively increased activity on both sides after sertraline when contrasted with temporal and some occipital areas. Sertraline was associated with a significantly increased relative metabolic rate in right parietal lobe and in left occipital area 19, and a decreased metabolic rate in right occipital area 18. Other areas that differed between controls and a larger cohort of 39 depressive patients--including medial frontal lobe, cingulate gyrus, and thalamus--also showed a normalization of metabolic rate after sertraline.
authors.affiliation: Department of Psychiatry, Mt. Sinai School of Medicine, New York, New York 10029-6574, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Buchsbaum
authors.forename: J
authors.initials: J
authors.lastname: Wu
authors.forename: B V
authors.initials: BV
authors.lastname: Siegel
authors.forename: E
authors.initials: E
authors.lastname: Hackett
authors.forename: M
authors.initials: M
authors.lastname: Trenary
authors.forename: L
authors.initials: L
authors.lastname: Abel
authors.forename: C
authors.initials: C
authors.lastname: Reynolds
mesh_terms: D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism*; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000187:drug effects*; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000378:metabolism; D003866:Depressive Disorder / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000523:psychology; D004292:Dominance, Cerebral / Q000187:drug effects / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006179:Gyrus Cinguli / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D020280:Sertraline; D013788:Thalamus / Q000000981:diagnostic imaging / Q000187:drug effects*; D014055:Tomography, Emission-Computed
chemical_list: D000928:Antidepressive Agents; D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18; D015057:1-Naphthylamine; D003847:Deoxyglucose; D020280:Sertraline